1647 VFW

AUS D & TOM DE LES

Customer Number: 22,852 Attorney Docket No. 4853.0068-00000

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	application of:	)
Katsuł	niko MIKOSHIBA et al.	) Group Art Unit: 1647
Applic	eation No.: 09/832,189	) Examiner: Sharon L. Turner
Filed:	April 11, 2001	) Confirmation No.: 1135
For:	TRUNCATED REELIN PROTEIN AND DNA ENCODING THE SAME	) )

## Mail Stop Amendment

Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Two of the documents were cited in the prosecution of co-pending and possibly related Application No. 09/897,438. Applicants also enclose a copy of an Office Action mailed July 13, 2004, in co-pending and possibly related Application No. 09/897,438. While Applicants believe that the Examiner is aware of these documents, Applicants provide them now for the Examiner's specific consideration and to ensure that the file is complete.

01 FC:1806

Applicants respectfully request that the Examiner consider the documents and indicate

that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists

and does not constitute an admission that the listed documents are material or constitute "prior

art." If the Examiner applies any of the documents as prior art against any claim in the

application and Applicants determine that the cited document(s) do not constitute "prior art"

under United States law, Applicants reserve the right to present to the Office the relevant facts

and law regarding the appropriate status of the document(s).

Applicants further reserve the right to take appropriate action to establish the patentability

of the claimed invention over the listed documents, should the documents be applied against the

claims of the present application.

If there is any further fee due in connection with the filing of this Statement, please

charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, L.L.P.

Dated: August 4, 2004

Jennifer L. Ellie

Reg. No. 50.584

-2-

## **INFORMATION DISCLOSURE CITATION**

			(AIPE)
Atty. Docket No.	4853.0068-00000	Serial No. 09/832,189	100
Applicant	Katsuhiko MIKOSHIBA et al.	Group: 1647	AUG 0 4 2004
Filing Date	April 11, 2001	Confirmation No. 1135	TEN SE
			TO BOTH AT

	U.S. PATENT DOCUMENTS					
Examiner Initial*	Document Number	Issue/ Publication Date	Name	Class	Sub Class	Filing Date If Appropriate
	U.S. Application No. 09/897,438 (including copy of Office Action dated July 13, 2004, from prosecution of U.S. Application No. 09/897,438)		Mikoshiba et al.			07/03/01

FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
			<u> </u>			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
	Nakajima, K. et al., 1997, "Disruption of hippocampal development <i>in vivo</i> by CR-50 mAb against Reelin," Proc. Natl. Acad. Sci. USA, 94: 8196-8201.			
	Miyata, T. et al., 1997, "Regulation of Purkinje Cell Alignment by Reelin as Revealed with CR-50 Antibody," J. of Neuroscience, 17(10): 3599-3609.			

Examiner	Da	te Considered
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 144	9 Patent and Tr	ademark Office - U.S. Department of Commerce